AR064268A1 - Sistema terapeutico transdermico para administracion del principio activo buprenorfina - Google Patents

Sistema terapeutico transdermico para administracion del principio activo buprenorfina

Info

Publication number
AR064268A1
AR064268A1 ARP070105127A ARP070105127A AR064268A1 AR 064268 A1 AR064268 A1 AR 064268A1 AR P070105127 A ARP070105127 A AR P070105127A AR P070105127 A ARP070105127 A AR P070105127A AR 064268 A1 AR064268 A1 AR 064268A1
Authority
AR
Argentina
Prior art keywords
administration
therapeutic system
transdermal therapeutic
active principle
buprenorfine
Prior art date
Application number
ARP070105127A
Other languages
English (en)
Original Assignee
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann Therapie Syst Lts filed Critical Lohmann Therapie Syst Lts
Publication of AR064268A1 publication Critical patent/AR064268A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medical Informatics (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicacion 1: Sistema terapéutico transdérmico para la administracion buprenorfina a la piel que comprende una capa posterior impermeable al principio activo, como mínimo una capa matriz que se adhiere por contacto y contiene el principio activo buprenorfina y como mínimo un ácido carboxílico y eventualmente una capa de proteccion que se retira antes del uso, caracterizado porque la capa matriz está constituida sobre la base de polisiloxanos o poliisobutilenos y esta solucion está dispersada en forma en formas de pequenas gotas en la capa matriz
ARP070105127A 2006-11-21 2007-11-19 Sistema terapeutico transdermico para administracion del principio activo buprenorfina AR064268A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006054731A DE102006054731B4 (de) 2006-11-21 2006-11-21 Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie

Publications (1)

Publication Number Publication Date
AR064268A1 true AR064268A1 (es) 2009-03-25

Family

ID=39326133

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105127A AR064268A1 (es) 2006-11-21 2007-11-19 Sistema terapeutico transdermico para administracion del principio activo buprenorfina

Country Status (26)

Country Link
US (5) US9308202B2 (es)
EP (2) EP2769714B1 (es)
JP (2) JP5763296B2 (es)
KR (1) KR101444967B1 (es)
CN (1) CN101528207B (es)
AR (1) AR064268A1 (es)
AU (1) AU2007323387B2 (es)
BR (1) BRPI0719115B8 (es)
CA (1) CA2670290C (es)
CY (2) CY1118154T1 (es)
DE (1) DE102006054731B4 (es)
DK (2) DK2769714T3 (es)
ES (2) ES2543977T3 (es)
HK (2) HK1132921A1 (es)
HU (2) HUE026978T2 (es)
IL (2) IL198743A (es)
IN (1) IN2009CN02662A (es)
MX (2) MX2009005341A (es)
NZ (1) NZ575500A (es)
PL (2) PL2094249T3 (es)
PT (1) PT2769714E (es)
RU (1) RU2484822C2 (es)
SI (2) SI2094249T1 (es)
TW (1) TWI411452B (es)
WO (1) WO2008061625A2 (es)
ZA (1) ZA200901695B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
TWI630208B (zh) 2008-12-08 2018-07-21 歐陸斯迪公司 二氫羥戊甲嗎啡
EP2468274B1 (de) * 2010-12-14 2015-07-01 Acino AG Transdermales therapeutisches System zur Verabreichung eines Wirkstoffs
DE102011076653A1 (de) * 2011-05-27 2012-11-29 Acino Ag Transdermales therapeutisches System enthaltend Buprenorphin und eine alpha-Hydroxysäure
US20130017259A1 (en) 2011-07-06 2013-01-17 The Parkinson's Institute Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
MX352795B (es) 2011-12-12 2017-12-07 Lts Lohmann Therapie Systeme Ag Sistema de administracion transdermica que comprende buprenorfina.
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2882870C (en) 2012-08-24 2020-12-15 Integurx Therapeutics, Llc Chemical compositions and methods for enhancing transdermal delivery of therapeutic agents
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
AU2013205080B2 (en) * 2012-12-12 2016-07-07 Lts Lohmann Therapie-Systeme Ag Transdermal Delivery System
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2014100599A1 (en) * 2012-12-21 2014-06-26 Teikoku Pharma Usa, Inc. Compositions and methods for transdermal delivery of hormones and other medicinal agents
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN103893154A (zh) * 2012-12-26 2014-07-02 江苏康倍得药业有限公司 包含丁丙诺啡的透皮给药***
WO2014105480A1 (en) * 2012-12-28 2014-07-03 Teikoku Pharma Usa, Inc. Extended buprenorphine transdermal delivery compositions and methods for using the same
JP5768222B2 (ja) * 2013-03-01 2015-08-26 パナソニックＩｐマネジメント株式会社 転写装置および印刷装置
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
GB2529789A (en) * 2013-06-04 2016-03-02 Lohmann Therapie Syst Lts Transdermal Delivery system
ES2703623T3 (es) * 2013-06-28 2019-03-11 Purdue Pharma Lp Antagonistas opioides para uso en el tratamiento de una arritmia inducida por analgésicos opioides
CA2916183C (en) 2013-07-03 2022-03-29 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system with electronic component
EP2921184A1 (de) 2014-03-19 2015-09-23 LTS LOHMANN Therapie-Systeme AG Überpflaster mit verbesserter Verträglichkeit und einer langen Haftungsdauer und Verfahren zu seiner Herstellung
CA2948221C (en) 2014-05-20 2022-11-22 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
WO2015177204A1 (en) 2014-05-20 2015-11-26 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system containing rotigotine
EP3145503A1 (en) 2014-05-20 2017-03-29 LTS Lohmann Therapie-Systeme AG Method for adjusting the release of active agent in a transdermal delivery system
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
US10213586B2 (en) 2015-01-28 2019-02-26 Chrono Therapeutics Inc. Drug delivery methods and systems
CN107660207B (zh) 2015-03-10 2020-09-29 罗德科技公司 丁丙诺啡乙酸盐及用于制备丁丙诺啡的方法
AU2016228779A1 (en) 2015-03-12 2017-09-07 Chrono Therapeutics Inc. Craving input and support system
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017048595A1 (en) * 2015-09-14 2017-03-23 Amneal Pharmaceuticals Llc Transdermal delivery system
AR102214A1 (es) * 2015-10-08 2017-02-15 Amarin Tech S A Un dispositivo para la administración transdermal de buprenorfina
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
EP3435977A4 (en) 2016-04-01 2019-10-16 Therapeuticsmd, Inc. PHARMACEUTICAL COMPOSITION OF STEROID HORMONE
WO2018129304A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
EP3678646B1 (en) * 2017-09-04 2021-09-29 LTS Lohmann Therapie-Systeme AG Transdermal delivery system including an emulsifier
WO2019064026A1 (en) 2017-09-29 2019-04-04 Orexo Ab NEW PHARMACEUTICAL COMPOSITIONS
DE102017127433A1 (de) * 2017-11-21 2019-05-23 Lts Lohmann Therapie-Systeme Ag TTS auf Basis von klebenden Weichmacher-Polymer-Matrices
JP2021517572A (ja) * 2018-03-13 2021-07-26 エルテーエス ローマン テラピー−ジステーメ アーゲー シリコーンアクリルハイブリッドポリマーを含む経皮治療システム
AU2019279884A1 (en) 2018-05-29 2020-12-10 Morningside Venture Investments Limited Drug delivery methods and systems
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions
US11752114B2 (en) 2019-04-17 2023-09-12 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system
JP7173415B2 (ja) * 2020-08-19 2022-11-16 東洋インキＳｃホールディングス株式会社 貼付剤

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3474101A (en) 1960-09-05 1969-10-21 Reckitt & Sons Ltd Thebaine and oripavine derivatives
GB1136214A (en) 1965-06-15 1968-12-11 Reckitt & Sons Ltd Thebaine and oripavine derivatives
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
CA2002299A1 (en) * 1988-11-10 1990-05-10 Eugene G. Drust Compositions for the transdermal delivery of buprenorphine salts
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
DE3939376C1 (es) 1989-11-29 1991-05-08 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De
DE4446600A1 (de) 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
DE19922662C1 (de) 1999-05-18 2000-12-28 Sanol Arznei Schwarz Gmbh Transdermales therapeutisches System (TTS) Tolterodin enthaltend
DE19958554C2 (de) * 1999-07-02 2002-06-13 Lohmann Therapie Syst Lts Mikroreservoirsystem auf Basis von Polysiloxanen und ambiphilen Lösemitteln und ihre Herstellung
JP4428899B2 (ja) 1999-07-02 2010-03-10 エルテーエス ローマン テラピー−ジステーメ アーゲー ポリシロキサンおよび両親和性溶媒を基にした微小貯蔵所系
BR0108379A (pt) 2000-02-08 2002-11-05 Euro Celtique Sa Composições de liberação controlada contendo agonista e antagonista opióide, método para a preparação de uma formulação em dosagem de analgésico opióide de liberação controlada com potência analgésica aumentada e sistema de administração através da derme para um analgésico opióide
US6682757B1 (en) 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
JP2004525960A (ja) 2001-02-16 2004-08-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 尿失禁、特に切迫尿失禁の治療用経皮デリバリーディバイスの製造にブプレノルフィンを使用する方法
DE10141651B4 (de) 2001-08-24 2007-02-15 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System (TTS) mit dem Wirkstoff Fentanyl und Verfahren zu seiner Herstellung
DE10213772A1 (de) 2002-03-27 2003-10-09 Gruenenthal Gmbh Zusammenhängende Einheit aus vereinzelbaren transdermalen therapeutischen Systemen
US20050118245A1 (en) 2002-03-27 2005-06-02 Wilsmann Klaus M. Assembled unit consisting of individually separable, transdermal, therapeutic systems
US20050191340A1 (en) * 2002-08-09 2005-09-01 Gruenenthal Gmbh Opioid-receptor antagonists in transdermal systems having buprenorphine
DK1526848T3 (da) * 2002-08-09 2007-10-22 Gruenenthal Gmbh Opiod-receptorantagonister i transdermale systemer med buprenorphin
NZ539936A (en) 2002-12-13 2007-06-29 Euro Celtique Sa Transdermal buprenorphine dosage regimen for analgesia
RU2324372C2 (ru) 2003-03-25 2008-05-20 Моринда, Инк. Селективное ингибирование продукции эстрогена и обеспечение эстрогенного действия в организме человека
DE102004045599A1 (de) 2004-09-17 2006-03-23 Grünenthal GmbH System zur sequentiellen, transdermalen Verabreichung von systemisch wirksamen Substanzen
DE102004062647A1 (de) 2004-12-21 2006-06-29 Kronotec Ag Holzfaserdämmstoffplatte bzw.- matte
DE102004062614B4 (de) 2004-12-24 2011-12-29 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit aktivierbarer Übersättigung und kontrollierter Permeationförderung sowie Verfahren zu dessen Herstellung
MX352795B (es) 2011-12-12 2017-12-07 Lts Lohmann Therapie Systeme Ag Sistema de administracion transdermica que comprende buprenorfina.
AU2013205080B2 (en) 2012-12-12 2016-07-07 Lts Lohmann Therapie-Systeme Ag Transdermal Delivery System
GB2529789A (en) 2013-06-04 2016-03-02 Lohmann Therapie Syst Lts Transdermal Delivery system

Also Published As

Publication number Publication date
EP2769714B1 (de) 2015-05-06
SI2769714T1 (sl) 2015-09-30
PL2094249T3 (pl) 2017-11-30
PL2769714T3 (pl) 2015-12-31
BRPI0719115A2 (pt) 2013-12-10
ZA200901695B (en) 2009-12-30
US20180289698A1 (en) 2018-10-11
BRPI0719115B8 (pt) 2021-05-25
US20100119585A1 (en) 2010-05-13
HK1132921A1 (en) 2010-03-12
CY1118154T1 (el) 2017-06-28
TW200836776A (en) 2008-09-16
IN2009CN02662A (es) 2015-08-07
WO2008061625A3 (de) 2008-09-18
IL245290A0 (en) 2016-06-30
CY1117770T1 (el) 2017-05-17
MX2009005341A (es) 2009-06-01
EP2094249B1 (de) 2016-04-13
EP2769714A1 (de) 2014-08-27
HUE026978T2 (en) 2016-08-29
US20160175447A1 (en) 2016-06-23
NZ575500A (en) 2011-12-22
IL198743A (en) 2016-05-31
AU2007323387B2 (en) 2014-01-09
JP5882970B2 (ja) 2016-03-09
BRPI0719115B1 (pt) 2019-04-24
JP2014028844A (ja) 2014-02-13
US20170224676A1 (en) 2017-08-10
WO2008061625A2 (de) 2008-05-29
ES2543977T3 (es) 2015-08-26
DE102006054731A1 (de) 2008-05-29
KR101444967B1 (ko) 2014-09-26
CA2670290C (en) 2016-05-31
RU2009123368A (ru) 2010-12-27
MX344241B (es) 2016-12-07
JP2010510259A (ja) 2010-04-02
RU2484822C2 (ru) 2013-06-20
HUE028971T2 (en) 2017-01-30
US20190192506A1 (en) 2019-06-27
DE102006054731B4 (de) 2013-02-28
JP5763296B2 (ja) 2015-08-12
IL198743A0 (en) 2010-02-17
CA2670290A1 (en) 2008-05-29
AU2007323387A1 (en) 2008-05-29
DK2769714T3 (en) 2015-08-03
KR20090082410A (ko) 2009-07-30
CN101528207B (zh) 2012-12-26
HK1200373A1 (en) 2015-08-07
TWI411452B (zh) 2013-10-11
ES2581574T3 (es) 2016-09-06
SI2094249T1 (sl) 2016-07-29
EP2094249A2 (de) 2009-09-02
US9308202B2 (en) 2016-04-12
DK2094249T3 (en) 2016-08-01
PT2769714E (pt) 2015-08-05
CN101528207A (zh) 2009-09-09

Similar Documents

Publication Publication Date Title
AR064268A1 (es) Sistema terapeutico transdermico para administracion del principio activo buprenorfina
AR055552A1 (es) Preparacion topica refrescante para parches y metodos para utilizar la misma
ECSP099635A (es) Formulaciones líquidas que forman una capa dérmica para la liberación de fármacos a la piel
AR097045A2 (es) Sistema terapéutico transdérmico
CL2014001029A1 (es) Forma de dosificacion farmaceutica solida oral de liberacion extendida que comprende una formulacion matricial que comprende un agente activo en forma de comprimido o multiparticulado; agente activo es un analgesico opioide; y uso en el tratamiento del dolor. (div. sol. 499-2012).
AR048827A1 (es) Aparato y metodo para la administracion transdermica de agentes basados en fentanil
MX2009012273A (es) Dispositivos de suministro transd?rmico que aseguran la liberaci?n mejorada de un principio activo a trav?s de una interfaz biol?gica.
AR084691A1 (es) Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel
AR063446A1 (es) Sistema de administracion para el tratamiento remoto de un animal
AR046697A1 (es) Metodo y sistema de administracion transdermica de agente asistido por frecuencia
CL2012000446A1 (es) Uso de una formulación vesicular tópica que comprende uno o más fosfolípidos y uno o más tensoactivos en una razón molar de 1:1 a 25:1 de fosfolípidos a tensoactivos, para el tratamiento de trastornos dermatosos inflamatorios.
AR051968A1 (es) Metodos y composiciones que utilizan inhibidores de jnk para el tratamiento y manejo de la lesion del sistema nervioso central
CO6361907A2 (es) Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo
AR093940A1 (es) Sistema de liberacion transdermica, metodo de preparacion
AR026040A1 (es) Sistema terapeutico transdermal que contiene clorhidrato de tulobuterol para la administracion del broncodilatador tulobuterol a traves de la piel
BR112014009712A2 (pt) dispositivos implantáveis para a administração de agentes bioativos
PL1684846T3 (pl) Urządzenie do transdermalnego podawania substancji czynnych
ECSP109960A (es) Gel conteniendo pirfenidona
ES2646737T3 (es) Sistema terapéutico transdérmico para clorhidrato de ácido 5-aminolevulínico
CL2010000524A1 (es) Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales.
MX2015007824A (es) Formulaciones parasiticidas transdermicas.
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
EA201300648A1 (ru) Трансдермальная терапевтическая система (tts), содержащая ротиготин
CL2008002466A1 (es) Composicion farmaceutica topica anhidra que comprende un vasodilatador y un vehiculo aceptable; uso de la composicion anhidra topica en las areas genitales para obtener bienestar sexual mejorado.
AR028525A1 (es) Sistema terapeutico transdermal para la administracion de lerisetron

Legal Events

Date Code Title Description
FB Suspension of granting procedure